Krystal Biotech Inc (KRYS)
NASDAQ · Healthcare · Biotechnology
Krystal Biotech Inc is a Healthcare company with a market capitalization of $10.97B and a trailing P/E ratio of 49.8.
5-Year Price History
Latest Annual Financials · FY ending December 31, 2025
Recent Quarterly Earnings (EPS)
| Quarter | Reported | Actual EPS | Estimate | Surprise |
|---|---|---|---|---|
| Q1 2026 | May 4, 2026 | $1.83 | $1.42 | +28.9% |
| Q4 2025 | February 17, 2026 | $1.70 | $1.58 | +7.6% |
| Q3 2025 | November 3, 2025 | $2.66 | $1.12 | +137.5% |
| Q2 2025 | August 4, 2025 | $1.29 | $1.44 | -10.4% |
| Q1 2025 | May 6, 2025 | $1.20 | $1.52 | -21.1% |
| Q4 2024 | February 19, 2025 | $1.53 | $1.85 | -17.4% |
Other Biotechnology Stocks
Frequently Asked Questions
What is Krystal Biotech Inc's market cap?
As of June 29, 2026, Krystal Biotech Inc (KRYS) has a market capitalization of $10.97B.
What is Krystal Biotech Inc's P/E ratio?
Krystal Biotech Inc trades at a trailing price-to-earnings (P/E) ratio of 49.8. Its forward P/E is 54.6.
Does Krystal Biotech Inc pay a dividend?
Krystal Biotech Inc does not currently pay a dividend.
What sector is KRYS in?
Krystal Biotech Inc is in the Healthcare sector, specifically the Biotechnology industry.
What was Krystal Biotech Inc's revenue?
In its latest reported fiscal year (ending December 31, 2025), Krystal Biotech Inc reported revenue of $389.13M and net income of $204.83M.
Ask your own questions about KRYS
Try mrmarket.ai freeData as of June 29, 2026. Figures are sourced from company filings and market data and may be delayed or revised. For informational purposes only — not investment advice.